PF-07321332
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| F1000-2MG | 2 mg | 96,00 | Add | |
| F1000-10MG | 10 mg | 270,00 | Add | |
| F1000-50MG | 50 mg | 630,00 | Add | |
| F1000-100MG | 100 mg | 939,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Please inquire a quote for two or more UBPBio products
PF-07321332 is an orally active covalent inhibitor of the 3C-like protease by direct binding of the catalytic cysteine 145. 3CL protease cleaves polyproteins 1a and 1ab of SARS-CoV-2, a step required for reproduce the virus. The PF-07321332/ritonavir combination drug (trade name Paxlovid) is efficient for the treatment of COVID-19 as, in November 2021, Pfizer announced phase 2/3 clinal trial results that the drug treatment reduced 89% in hospitalizations when given within three days after symptom onset. This product is for research use only.
| Category | Biochemicals |
| Supplier | UBPBio |
| Regulatory Status | RUO |
| Format | Powder; no buffer |
| Molecular Weight | 499.53 |
| Storage Conditions | -20°C |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.ubpbio.com |
| Shipping Details | Ambient temp. |
| Material Safety Data Sheet | Download PDF |
